golf ... Same "kneejerk" reaction as you. But we don't know what goes on in the board room, real world expectations within the board room, or other deals in place or set up with Covid trial success. Agreed though, what a confidence and awe inspiring concept it would have been for Hepa to exercise at $3.91 today. And it does inspire "issues" thoughts, or a desire to not help and get closer to the IP claim. But, unless Covid flops, getting $6m somewhere should not be a huge problem?

What REALLY has my interest, and as you pointed out, is why Hepa and Ori have been unable (or unwilling) to drive progress in their sphere of influence (China/Asia), especially with Covid originating there. It could represent huge progress for Apabetalone/RVX, generate revenues more quickly, and it would even be a "good look" for China contributing and now being part of the solution for Covid. Weird.